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Abstract Brain white matter hyperintensities are more
prevalentinmigrainepatientsthaninthegeneralpopulation,
but the pathogenesis and the risk factors of these hyperin-
tensities are not fully elucidated. The authors analyzed the
routine clinical data of 186 migraine patients who were
referred to the Outpatient Headache Department of the
Department of Neurology, Medical School, University of
Pe ´cs, Hungary between 2007 and 2009: 58 patients with
whitematter hyperintensitiesand128patients withoutwhite
matter hyperintensitieson3 TMRI.Signiﬁcantassociations
between the presence of white matter hyperintensities and
longer disease duration (14.4 vs. 19.9 years, p = 0.004),
higher headache frequency (4.1 vs. 5.5 attacks/month,
p = 0.017), hyperhomocysteinemia (incidence of hyperin-
tensity is 9/9 = 100%, p = 0.009) and thyroid gland dys-
function (incidence of hyperintensity is 8/14 = 57.1%,
p = 0.038) were found. These data support the theory that
boththediseasedurationandtheattackfrequencyhaveakey
role in the formation of migraine-related brain white matter
hyperintensities, but the effects of comorbid diseases may
also contribute to the development of the hyperintensities.
Keywords Migraine  White matter hyperintensity 
Disease duration and attack frequency  Stroke risk factors
Introduction
Migraine is a complex disorder of the brain, and its patho-
mechanism is intensively investigated. Migraine is not as
benign a disease as it was thought before the imaging era
since migraine is an independent risk factor for deep white
matter lesions, silent posterior circulation territory infarcts,
and infratentorial hyperintense lesions [1–4]. Migraine
patientshaveanalmostfourfoldgreaterrisktodevelopwhite
matter lesions than non-migraine controls [5], and the
prevalence of these lesions is higher in migraine with aura
than in migraine without aura [4]. The risk of developing
white matter lesions is higher in female migraineurs and in
patients with higher attack frequency and longer disease
duration[4,6].Furthermore,itseemsthatbrainwhitematter
lesions do not correlate with age [7, 8]. It is also known that
beyond the existing relation between migraine and stroke,
there is also an association between migraine and coronary
heart disease [9, 10]. Since the risk of these severe compli-
cations is low in the general population, it is not possible to
identify which migraine patients will develop a cerebro-
vascular or cardiovascular event [10].
The clinical signiﬁcance of white matter hyperintensities
(WMH) is uncertain and the pathogenesis of these lesions
is likely multifactorial. A number of pathophysiological
mechanisms have been proposed including attack-related
oligemia and focal hypoperfusion [3, 11], glutamatergic
excitotoxicity [11, 12], immune-based white matter
demyelination [13], and mitochondrial dysfunction [14].
Several studies considered the role of inﬂammation as a
vascular risk for brain white matter lesions in migraine
[15–17]. Elevated C-reactive protein found in migraine
patients is a sensitive indicator of active systemic inﬂam-
mation and a marker of oxidative stress [15]. Increased
proinﬂammatory cytokines (IL-1, IL-6, TNF-a) have been
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interictal periods [16, 17]. Repeated sterile vascular
inﬂammation results in endothelial injury of the cranial
blood vessels, cranial arteriopathy, and consequent
thrombosis [18, 19]. It has been suggested that cortical
spreading depression causes disruption of the blood brain
barrier through a matrix metalloproteinase-9-dependent
cascade mechanism which may result in local tissue dam-
age [20]. It is also known that endothelial dysfunction
associates with an increased rate of cerebrovascular
ischemic events, and genetic factors (such as angiotensin-
converting enzyme insertion/deletion, methylenetetrahy-
drofolate reductase C677T polymorphisms, and von
Willebrand factor activity) which increase the susceptibil-
ity of endothelial dysfunction have been linked to migraine
[21, 22].
Although migraineurs, particularly with aura, have a
higher cardiovascular risk proﬁle than individuals without
migraine[23],thepresenceofwhitematterlesionsprovedto
be independent of a history of hypertension, diabetes,
smoking, hypercholesterolemia, hyperhomocysteinemia,
patent foramen ovale with right-to-left shunt, and oral con-
traceptive use [5, 24, 25]. Associations with antiphospho-
lipid antibodies (anticardiolipin antibodies, lupus
anticoagulans) and abnormal coagulation parameters (anti-
thrombin-III, protein S, protein C) were also not found [26].
Because of the high prevalence of white matter hyperin-
tensities, and the partly contradictory and uncertain etio-
logicaldata,wehaveinvestigatedthepossibleriskfactorsfor
subclinical brain white matter hyperintensities in our own
migraine patients by analyzing their routine clinical data.
Patients and methods
Subjects and studies
Subjects included in this study were referred to the Out-
patient Headache Department of the Department of Neu-
rology, Medical School, University of Pe ´cs, Hungary
between 2007 and 2009. All the patients who were chosen
for the study met the criteria of migraine patients as deﬁned
by the International Headache Society [27]. Further,
patients were also selected based on the lack of major
comorbidities, such as hypertension, cardiac disease, dia-
betes, thyroid gland dysfunction, oncological and haema-
tological diseases, infectious diseases (e.g. HIV, hepatitis),
central nervous system demyelination (e.g. multiple scle-
rosis), and genetically inherited disorders (e.g. CADASIL).
Altogether 186 migraine patients were investigated in the
study (141 patients without aura, 45 patients with aura, age
range 18–58 years, mean age 36.4 years, SD: 8.9; 156
females and 30 males). Based on the ﬁndings of brain
magnetic resonance imaging (MRI) studies, patients were
divided into two groups: patients with WMH (WMH?
group, n = 58, mean age 40.2 year, 54 patients had
supratentorial hyperintensities, 4 patients had cerebellar
hyperintensities) and patients without WMH (WMH-
group, n = 128, mean age 34.9 year).
All participants underwent a structured clinical exami-
nation (history taking, physical examination, blood pres-
sure measurement, serum and urine tests, brain MRI study)
to identify comorbid medical disorders. Gender, migraine
type, disease duration, attack frequency, history of smoking
and taking oral contraceptives, serum cholesterol (refer-
ence range 4.00–5.60 mmol/l) and low-density lipoprotein
(LDL) (reference range 0.00–3.40 mmol/l), uric acid (ref-
erence range 180–350 lmol/l), homocysteine levels (ref-
erence range 5.00–15.00 lmol/l), and thyroid-stimulating
hormone levels (reference range 0.27–4.20 mU/l) with
thyroxine and triiodothyronine when necessary were rou-
tinely examined. Subclinical hypo- and hyperthyroidism
was diagnosed when peripheral thyroid hormone levels
were within normal reference laboratory range but serum
thyroid-stimulating hormone levels were mildly elevated or
decreased. In all cases when aura symptoms and/or WMH
were present, patients were tested for vasculitis (antinu-
clear antibody, antineutrophil cytoplasmic autoantibody,
antiphospholipid antibody, lupus anticoagulant), for Lyme
disease (serum ELISA screening with Western blot test-
ing), and for patent foramen ovale (transthoracic and
transesophageal echocardiography).
MRI protocol
The brain MRI examinations were carried out with an MR
scanner operating at 3 T (Siemens Trio Tim, 12 channel
head coil). A qualiﬁed neuroradiologist who was blinded to
migraine diagnosis and clinical data rated the WMH.
WMH were considered if visible as hyperintense on T2-
weighted and FLAIR images, without hypointensity on T1-
weighted scans, and were larger than 3 mm [28].
Statistical analysis
Statistical analysis was performed using the SPSS 15.0
statistical package (SPSS Inc., Chicago, IL, USA). Chi-
square tests were performed to assess the difference
between the WMH? and WMH- groups in relation to
migraine type, disease duration, attack frequency, gender,
smoking, cholesterol, LDL, uric acid, and thyroid-stimu-
lating hormone levels. To examine the disease duration,
patient groups were created in which the disease duration
increased by 5 years in each group (0–5, 5–10, etc.). Fur-
thermore, patients were divided into three groups by
monthly attack frequency (rare: 0–1 attacks/month,
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attacks/month). Since homocysteine level was measured
only in 60 patients, and thyroid gland dysfunction was
found only in 14 patients, a Fisher’s exact test was used to
assess the difference between the groups. Both the disease
duration and attack frequency were used as dichotomous
variables when contingency tables were created and eval-
uated. Chi-square tests and Fisher’s exact test were used for
these evaluations. The non-parametric Mann–Whitney test
was also applied to investigate the role of the disease
duration and the attack frequency in the formation of
WMH in different groups, including all patients and
migraine subgroups (patients without and with aura). In
this analysis, the disease duration and the attack frequency
were analyzed as continuous variables. Finally, a binary
logistic regression was also performed to predict the
presence of WMH from a set of independent variables. For
this analysis homocysteine was not used due the number of
the tested patients. Group comparisons were not performed
for oral contraceptives because most of the migraineurs
were female and there was contraceptive use in the past
and/or current medical history in almost all cases. A value
of p\0.05 was considered to be signiﬁcant.
Results
1. There was no statistical difference between females
(n = 48 out of 156, 30.7%) and males (n = 10 out of
30, 33.3%), as well as between migraine patients
without aura (n = 42 out of 141, 30.5%) and patients
with aura (n = 16 out of 45, 35.6%) in relation to the
presence of WMH.
2. The number of patients with WMH increased with the
increase of disease duration; in patients with above 20
migraine years hyperintensities were signiﬁcantly
more frequent than in those with less than 20 years
of duration (under 20 years n = 28/120, 23.3%, above
20 years in n = 30/66, 45.6%, p = 0.007). When
examining the association between the disease dura-
tion and the presence of WMH according to migraine
type, it was found that both migraine patients without
and with aura have a longer disease duration with
WMH, than patients without WMH (Table 1).
3. Although the proportion of migraine patients with
WMH increased with the monthly migraine attack
frequency (0–1 attack/month: n = 7/37, 18.9%, 2–7
attacks/month: n = 36/114, 31.5%, C8 attacks/month:
n = 15/35, 42.9%), there was only a trend towards
statistical signiﬁcance (p = 0.08) when the patients
were examined in three groups according to their attack
frequency.Conversely,whentheattackfrequencyofthe
WMH? group was compared to the attack frequency of
the WMH- group, a signiﬁcantly higher attack number
was found in the WMH? group (Table 1). When
examiningtheeffectofattackfrequencyonthepresence
of brain WMH in migraine subgroups, it was found that
migraine patients without aura and with WMH have a
higher attack frequency than patients without aura and
without WMH (Table 1). In patients with aura the same
tendency was seen, but the difference was not statisti-
cally signiﬁcant (Table 1).
4. WMH did not occur more frequently in smokers
(n = 18/52, 34.6%) than in non-smokers (n = 40/134,
29.8%), but smoking was signiﬁcantly associated
(p = 0.001) with increased monthly attack frequency
(\5 attacks/month: n = 87/134, 64.9% in non-smok-
ers, n = 47/134, 35.0% in smokers, C5 attacks/month:
n = 20/52, 38.4% in non-smokers, n = 32/52, 61.5%
in smokers).
Table 1 Differences between the WMH- and WMH? groups in relation to disease duration and attack frequency in migraine patients without
and with aura
Patient number Disease duration (years) p value Attack frequency (attack/month) p value
All patients
WMH- 128 14.3 ± 8.5 0.004 4.1 ± 3.0 0.017
WMH? 58 19.9 ± 11.6 5.5 ± 3.6
Patients without aura
WMH- 99 14.7 ± 8.7 0.030 4.6 ± 3.1 0.016
WMH? 42 19.7 ± 11.7 6.2 ± 3.6
Patients with aura
WMH- 29 13.1 ± 7.9 0.047 2.4 ± 2.4 0.067
WMH? 16 20.3 ± 11.8 3.5 ± 3.0
WMH- patients without white matter hyperintensities, WMH? patients with white matter hyperintensities
The diseases duration and attack frequency values are presented in mean ± 1S D
p values are based on Mann–Whitney statistical analysis
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1235. There was a signiﬁcant relation between abnormally
high serum homocysteine levels and the incidence of
brain WMH; out of 60 patients tested for serum
homocysteine 9 had WMH and homocysteine levels
were elevated in all 9 patients (p = 0.009).
6. Subclinical hypo- (n = 8) and hyperthyroidism
(n = 6) was detected in 14 patients (14/
186 = 7.5%). Out of these patients, eight had WMH
(4 patients in both groups, 8/14 = 57.1%). Statistical
analysis showed the subclinical thyroid dysfunction
occurred signiﬁcantly more frequently in the WMH?
group than in the WMH- group (p = 0.038).
7. Although the statistical analysis did not show an
increased risk of WMH in migraineurs with high
cholesterol ? LDL cholesterol (p = 0.06) and high
uric acid levels (p = 0.07), the cholesterol ? LDL
cholesterol and uric acid values were found more
frequently in the elevated range in the WMH? group
(n = 18/41, 43.9% for cholesterol ? LDL cholesterol,
n = 7/15, 46.6% for uric acid) than in the WMH-
group (n = 40/145, 27.5% for cholesterol ? LDL
cholesterol, n = 51/171, 29.8% for uric acid).
8. When the effects of all the predictor variables were
examined,onlytwogoodpredictorvariableswerefound:
the disease duration (p\0.01) and the attack frequency
(p\0.05)(Table 2).Therewasnosigniﬁcanteffectwith
all the other variables (p[0.1) (Table 2).
9. An elevated antiphospholipid antibody titer was only
found in one patient. Echocardiography showed a tiny
patent foramen ovale with right to left shunt in two
migraine patients with aura and with brain WMH.
There was no patient with pathologic Lyme serology.
Discussion
In this study, we have investigated possible risk factors for
brain WMH based on migraine history and blood tests. To
get more accurate data on those factors which may inﬂu-
ence the formation of WMH, diseases which can associate
with the presence of brain WMH without migraine,
including hypertension, were excluded from our study. We
found signiﬁcantly higher hyperintensity incidence in
patients with longer migraine duration, higher headache
frequency, subclinical hyper- and hypothyroidism, and
elevated plasma concentrations of homocysteine, while in
the cases of cholesterol and uric acid, there was a trend
towards statistical signiﬁcance. Statistical difference was
not found between migraine patients without and with aura
in relation to the presence of WMH, but most of the
patients in the WMH? group had only supratentorial signal
abnormalities [1]. There are differences between our results
and the previously documented ones, and we suppose that
these are based on the limitations of the performed studies
due to differences in patient selection and sample size.
The relation between disease duration and attack fre-
quency to the WMH is not surprising if we take into
account the pathophysiology of migraine [29]. During the
attack several intracranial pathologic processes are
detectable, including intracerebral haemodynamic changes,
local inﬂammatory responses, excessive neuronal activa-
tion and excitotoxicity, which may all lead to tissue dam-
age [30]. Although there are regional differences and
predilection sites for tissue damage, basically, the migraine
attack affects the whole brain [6, 30, 31]. It is known that
there are differences among migraine patients in relation to
the risk of the WMH. The risk depends not only on the
disease duration and frequency, but the migraine type,
attack duration, and comorbid conditions can also inﬂuence
it [4, 6]. The comorbid conditions are mainly routine stroke
risk factors and these may lead to tissue damage by direct
(e.g. blood vessel endothelium dysfunction, hypercoagu-
lation, embolization) or indirect (e.g. smoking) effects [21,
23, 32–41]. In our study, the occurrence of WMH was not
higher in smokers than in non-smokers, but smoking
increased the headache frequency, therefore smoking may
indirectly cause white matter hyperintensities. These data
are consistent with the previously reported ones showing
higher prevalence rates for headache amongst smokers
compared to non-smokers [32, 33].
Plasma homocysteine concentration is controlled by
genetic (MTHFR C677T mutation), nutritional (vitamins
Table 2 Results of binary logistic regression for white matter
hyperintensities
Examined variables p OR 95.0% CI for OR
Lower Upper
Step 1
Disease duration 0.090 1.046 0.993 1.103
Attack frequency 0.018 1.164 1.026 1.321
Age 0.913 0.997 0.947 1.049
Gender 0.865 1.087 0.414 2.855
Smoking 0.249 0.584 0.234 1.457
Thyroid function 0.289 0.637 0.277 1.465
Cholesterol 0.135 0.498 0.200 1.242
Uric acid 0.447 0.515 0.093 2.849
Step 7
Disease duration 0.005 1.051 1.015 1.089
Attack frequency 0.017 1.153 1.026 1.295
The table presents the p value, the odds ratio (OR) and the 95%
conﬁdence interval (CI) for the OR for all of the variables at Step 1
and for the variables that were signiﬁcant at Step 7 of the backward
stepwise elimination procedure
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123folate, B6, B12) and acquired (smoking, alcohol con-
sumption, renal diseases, malignancies, inﬂammation, daily
physical activity) factors [34]. It is also known that endo-
thelial asymmetric dimethylarginine has been linked with
elevated levels of homocysteine [35]. Conversely, asym-
metric dimethylarginine concentrations are substantially
elevated by native or oxidized LDL cholesterol [36]. Fur-
thermore, HDL-cholesterol levels were inversely correlated
to the homocysteine levels [37]. In this study, we did not
examine which factors could lead to an elevation of
homocysteine levels, only if the elevation itself was pres-
ent. Regardless of the provoking factors, elevated total
homocysteine concentration is an independent risk factor
for recurrent stroke [38] which may result from an endo-
thelial injury and altered coagulant properties of the blood
[39, 40]; however, it is still controversial whether mild
hyperhomocysteinemia is a causal factor. It has been found
that migraine patients with aura who are homozygotes for
methylene-tetrahydrofolate reductase (MTHFR) C677T
variant, are at risk for elevated levels of homocysteine, and
homocysteine-related endothelial dysfunction may be
involved in the initiation and maintenance of migraine
[21].
Although subclinical thyroid gland dysfunction was
found in few patients in our study, more than half of these
patients had brain WMH. Subclinical thyroid gland dys-
function can be a risk factor for WMH in migraine, but
currently there is no deﬁnite evidence to conﬁrm this.
Previously, in a large cross-sectional population-based
study, TSH levels were lower among headache patients,
especially migraineurs, than in those without headache
complaints [41]. It is also known that the endocrine func-
tion, including the plasma concentrations of TSH, is altered
in chronic migraine patients with high headache frequency
and frequent analgesic use [42]. In addition, a signiﬁcant
correlation was found between the duration of the disease
and the altered hormonal response [42]. Hyperthyroidism
can associate with atrial ﬁbrillation and cardioembolic
stroke and may lead to a hypercoagulability state [43].
Hypothyroidism is associated with a worse cardiovascular
risk factor proﬁle including elevated cholesterol and low-
density lipoprotein levels, diastolic hypertension, increased
homocysteine and C-reactive protein concentrations,
impaired thyroid hormone action on target tissue by
smoking, tendency toward decreased ﬁbrinolytic activity in
mild and moderate hypothyroidism, and endothelial dys-
function with progression to atherosclerosis [43].
We found WMH more frequently in our migraine
patients with elevated serum cholesterol and uric acid
levels, and we speculate that if there is a relation between
migraine and cholesterol and uric acids levels, this can be
based on altered endothelial dysfunction and migraine
attack frequency. Hyperlipoproteinemias can be familial in
origin but there are drugs and diseases (e.g. oral
contraceptives, hypothyroidism) which can cause second-
ary hyperlipoproteinemias or worsen underlying hyper-
lipoproteinemic states [44]. High levels of blood lipids and
free fatty acids are among the factors involved in triggering
migraine headache [45]. The presence of hypercholester-
olemia and dyslipidemia in patients with migraine may
increase the risk of vascular wall injury. Hypercholester-
olemia is associated with an increase in endothelial per-
meability, the retention of lipoproteins within the intima of
blood vessels, inﬂammatory cell recruitment and foam cell
formation ﬁlled with oxidative-LDLs, and ﬁnally these
processes progress to atherosclerotic plaque maturation
[46]. Cholesterol crystals, a component of human athero-
sclerotic plaques, could also cause an inﬂammatory
response and neuronal injury in the brain with persistent
activation of microglia and astrocytes via microemboliza-
tion [47]. Furthermore, a number of epidemiologic data
show that an elevated serum uric acid level is a powerful
predictor of an increased risk of a cardiovascular event
including stroke and silent brain infarcts [48] however, the
available data are contradictory. It is entirely plausible that
chronic elevations in serum uric acid levels have harmful
effects on platelet, smooth muscle, and endothelial function
[49], but the neuroprotective, antioxidant effect of high uric
acid levels may associate with improved outcome in the
peri-ictal period [50].
In conclusion, this study provides additional data on the
etiology of migraine-related WMH supporting the former
assumptions that a wide range of factors contribute to lesion
formation. These include attack-related intracerebral chan-
ges and direct or indirect effects of comorbid diseases.
Development in understanding the pathophysiology of
migraine and the pathology of WMH, the use of effective
therapy for migraine attack and prophylaxis, detection and
treatmentofvascularriskfactors,andavoidingsmokingmay
help to prevent the development of the hyperintensities.
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